Transgenomic Stands to Pocket $940K in Third-Party Stock Sale | GenomeWeb
NEW YORK (GenomeWeb News) — Transgenomic earlier this month said it hoped to pocket $937,500 in a private stock placement scheduled to close in February.
The company, which has been beset by financial challenges in recent months, said it would sell 250,000 shares of common stock of a company called Pinnacle Pharmaceuticals to New River Pharmaceuticals for $3.75 per share less certain liabilities, according to a Securities and Exchange Commission filing last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.